NICE opens NHS door to MS, CML and Hep C drugs

Patients with multiple sclerosis will be celebrating news that cost regulators for the National Health Service in England and Wales have approved funding for Novartis’ Gilenya, the world’s first pill for the disease.

The National Institute for Health and Clinical Excellence has issued guidance recommending Gilenya (fingolimod) for adults who have had an unchanged or increased relapse rate, or ongoing severe relapses compared to the previous year, despite having taken other medications. 

The decision means that, by July 25 this year, patients with highly active relapsing remitting (RRMS) forms of MS who are not responding to treatment with first-line interferon injections should have access to the drug on the NHS.

READ MORE, click here